Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Three Rivers acquires rights to hepatitis drug from Valeant
Valeant will receive from Three Rivers approximately $70.8 million in cash upon closing, and up to $20.5 million in two noncontingent payments over the following eighteen months. Under
Valeant will receive from Three Rivers approximately $70.8 million in cash upon closing, and up to $20.5 million in two noncontingent payments over the following eighteen months. Under
This randomized, multi-center, open-label Phase II study is designed to evaluate the efficacy and safety of HGS-ETR1 in combination with carboplatin and paclitaxel as first-line therapy in the
Among the terms of the settlement is a paid-up worldwide license under the patents at issue. The amount paid by Home Diagnostics will be recorded as an expense
Under the agreement, BioSphere has agreed to make payments to DuPont of up to $500,000 based upon the achievement of specified milestones. BioSphere and DuPont will share equally
The RESTORA I study is a multi-center, double-blind, randomized, placebo-controlled, active reference, parallel-group polysomnography study to confirm the efficacy and safety of almorexant in adult subjects with chronic
The R1507 antibody was created by Genmab under the company’s agreement with Roche and initiation of the trial will trigger a milestone payment to Genmab of $500,000. Lisa
This will be the first Phase II clinical trial for EHT 0202 and it will be a multi-center, double-blind trial, in which 135 patients will be randomized. The
Under the terms of the agreement, Merck Serono will make an upfront payment of E2 million to Flamel for investigating the therapeutic protein and Merck Serono will fund
Under the agreement, HGS has paid Aegera an upfront license fee of $15 million and has made an equity investment of C$5 million. Aegera will be entitled to
Aeras and Crucell began jointly developing this vaccine candidate, called AERAS-402, in 2004 using Crucell’s AdVac vaccine technology and PER.C6 manufacturing technology. A Phase I clinical trial launched